Recent advancements in our knowledge about immune checkpoint receptors, CTLA-4, and PD-1 in cancer immunogenicity and their inhibition led to a paradigm shift in cancer treatment strategies (Figure 1) [11,12]. The gene discussed is PDCD1; the disease is cancer.